Comparison of the effect of 17α- Hydroxy Progesterone caproate in prevention of preterm labor in twin pregnancies

Subject Areas : علوم پزشکی

Nooshin  Baba pour ¹ ()
Banafshe  Oladan ² ()
Marzieh  Mohajeri ³ ()

Received: 2017-06-06 Accepted : 2017-06-06 Published : 2012-05-21

Keywords: Twin pregnancy- Preterm labor- 17.alpha- hydroxyprogestrone,

Abstract :

Background and objective: There are indications that prophylactic administration of 17 alpha- hydroxyprogesterone caproate (17 alpha- OHP-C) could be beneficial in the treatment of women at risk for preterm delivery. Since twin pregnancy is commonly associated with prematurity the aim of this study was to evaluate the effect of 17α- Hydroxy Progesterone caproate in prevention of preterm labor in twin pregnancies. Methods: 66 women with twin pregnancy (33 in control and 33 in case group) were enrolled. 33 women with 16 to 20 weeks’ gestation were scheduled to receive randomly a single intramuscular injection of 250 mg of 17- OHPC every week until 30 weeks of gestation. Women in control group received no drugs. Two groups were similar considering meternal age and number of past pregnancies. Results: Mean age of women in control and progestron groups were 27.4± 3.9 and 26.5± 4.4 years. There was no significant differences between two groups in gestational age, admission in neonatal intensive care unit (NICU), presentation of fetus, birth weight of neonatal and meternal pain and bleeding. Administration of 17α- OHP-C caused no significant decrease in preterm labor (PTL). Although there was no significant differences in neonatal apgar at 5 minutes of birth, apgar at 1 minute of birth was significantly higher in case group (P=0.011). Conclusion: The administration of 17- alpha- OHP-C thus seems ineffective in the prevention of prematurity risks associated with twin pregnancy.  

References:

 

1. .Labor. In: Cunningham F.G, Leveno KJ, Bloom SL,  Hauth JC, Rouse DJ, Spong CY, editors. Williams obstetrics 23^rd ed. New York: McGraw-Hill; 2010. p. 804-841.


2. Kramer MS, Demissie K, Yang H, Platt RW, Sauve R, Liston R. The contribution of mild and moderate preterm birth to infant mortality. Fetal and Infant Health Study Group of the Canadian Perinatal Surveillance System. JAMA. 2000 Aug 16;284(7):843-9.


3. Briery CM, Veillon EW, Klauser CK, Martin RW, Chauhan SP, Magann EF, Morrison JC.Progesterone does not prevent preterm births in women with twins.South Med J. 2009 Sep;102(9):900-4.


4. Durnwald CP, Momirova V, Rouse DJ, Caritis SN, Peaceman AM, Sciscione A,et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17-α± hydroxyprogesterone caproate. J Matern Fetal Neonatal Med. 2010 Dec;23(12):1360-4.


5. Bornstein E, Proudfit CL, Keeler SM. Prematurity in twin pregnancies. Minerva Ginecol. 2009 Apr;61(2):113-26.


6. Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY,et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med. 2007 Aug 2;357(5):454-61.


7. Hartikainen-Sorri AL, Kauppila A, Tuimala R. Inefficacy of 17 alpha-hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstet Gynecol. 1980 Dec;56(6):692-5.


8. Gibbs R S,Karlan BY,Haney A F,Nygard I.Danforths Obstetrics and Gynecology.10th edition.New york:Lippincott Williams&Wilkins;2008.165-180.


9. Berek JS. Berek and Novak’s Gycenology. 14^th ed. Philladelphia:Lippncott Williams and wilkins; 2007. p.885-910.


10. Dudás I, Gidai J, Czeizel AE. Population-based case-control teratogenic study of hydroxyprogesterone treatment during pregnancy. Congenit Anom (Kyoto) 2006; 46: 194-8.


11. شهراز سعید،غازیانی طاهره.درسنامه جامع داروهای رسمی ایران.ایران فارما.چاپ سوم.تهران:موسسه انتشاراتی تیمورزاده(نشر طیب)؛1384.ص.363


12. Meis PJ, Klebanoff M, Thom E. prevention of recurrent preterm delivery by 17 alphahydroxyprogesterone caproate. N Engl Med. 2003; 384(11): 2379- 2385.


13. Senat MV, Porcher R, Winer N, Vayssière C, Deruelle P, Capelle M, Bretelle F, Perrotin F, Laurent Y, Connan L, Langer B, Mantel A, Azimi S, Rozenberg P; Groupe de Recherche en Obstétrique et Gynécologie. Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. Am J Obstet Gynecol. 2013 Mar;208(3):194 -8.


14. Grobman WA, Thom EA, Spong CY, Iams JD, Saade GR, Mercer BM, Tita AT, Rouse DJ, Sorokin Y, Wapner RJ, Leveno KJ, Blackwell S, Esplin MS, Tolosa JE, Thorp JM Jr, Caritis SN, Van Dorsten JP; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units (MFMU) Network.17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. Am J Obstet Gynecol. 2012 Nov;207(5):390 -8.


15. Tan PC, King AS, Vallikkannu N, Omar SZ. Single dose 17 alpha-hydroxyprogesterone caproate in preterm labor: a randomized trial. Arch Gynecol Obstet. 2012 Mar;285(3):585-90.


16. Caritis SN, Simhan HN, Zhao Y, Rouse DJ, Peaceman AM, Sciscione A, Spong CY, Varner MW, Malone FD, Iams JD, Mercer BM, Thorp JM Jr, Sorokin Y, Carpenter M, Lo J, Ramin SM, Harper M; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. Am J Obstet Gynecol. 2012 Nov;207(5):396-8.


17. Caritis SN, Sharma S, Venkataramanan R, Rouse DJ, Peaceman AM, Sciscione A, Spong CY, Varner MW, Malone FD, Iams JD, Mercer BM, Thorp JM Jr, Sorokin Y, Carpenter M, Lo J, Ramin S, Harper M; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation. Am J Obstet Gynecol. 2011 Jul;205(1):40.e1-8.


18. González-Quintero VH, de la Torre L, Rhea DJ, Tudela CM, Vazquez-Vera E, Desch C, Istwan NB. Impact of prior gestational age at preterm delivery on effectiveness of 17-alpha-hydroxyprogesterone caproate in practice. Am J Obstet Gynecol. 2010 Sep;203(3):257-262.


19. Combs CA, Garite T, Maurel K, Das A, Porto M.17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol. 2011 Mar;204(3):2211-8.


20. سالاری زهره,میرزایی سکینه,راوری علی,میرزایی طیبه. مقایسه شیاف واژینال پروژسترون و قرص ایزوکسوپرین خوراکی در افزایش زمان نهفته پس از کنترل زایمان زودرس. مجله دانشگاه علوم پزشکی رفسنجان. مهر و آبان 1391; 11(4):301-312.


21. ثقفی نفیسه,خادم نیره,مهاجری ترانه,شاکری محمدتقی,امینی مرجان. بررسی اثر α 17- هیدروکسی پروژسترون کاپروات در پیشگیری از زایمان زودرس. مجله زنان مامایی و نازایی ایران. خرداد و تیر 1390; 14(2):28-33.


22. اکبری سهیلا,بیرجندی مهدی,محتشم ندا. بررسی اثر شیاف پروژسترون در جلوگیری از زایمان زودرس و عوارض آن. مجله علمی دانشگاه علوم پزشکی کردستان. پاییز 1388; 14(3):11-19.


23. بهادری فاطمه,برنا صدیقه,شکویی نژاد مراغه صفورا,صحابی نوشین. اثر پروژسترون در افزایش زمان نهفته بعد از کنترل زایمان زودرس. مجله دانشکده پزشکی. خرداد 1387; 66(3):208-213.